Search

Displaying results 2721 - 2730 of 4246 in total
  1. Drug

    Vilobelimab

    go.drugbank.com/drugs/DB16416
    ApprovedInvestigational

    Vilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity. It consists of mouse anti-human complement factor 5a (C5a) monoclonal binding sites (variable regions ...

  2. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain [L3263].

  3. Drug

    Alpelisib

    go.drugbank.com/drugs/DB12015
    ApprovedInvestigational

    Alpelisib is marketed under the trade name Piqray and is available as oral tablets. … Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer [A179200] and colorectal cancer [A179203], are under ongoing investigations.

  4. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by shortened and partially functional dystrophin protein production.

  5. Drug

    Grapiprant

    go.drugbank.com/drugs/DB12836
    InvestigationalVet approved

    Grapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class. … [L4766] Grapiprant has been approved in March 2016 by the FDA's Center for Veterinary Medicine as a non-cyclooxygenase inhibiting NSAID for veterinary use.[A39836]

  6. Drug

    Xenon Xe-129

    go.drugbank.com/drugs/DB17386
    ApprovedInvestigational

    Lung MRIs are challenging due to the low proton density of this tissue, as well as the presence of artifacts due to respiration and cardiovascular pulsation movement and air–tissue interfaces.

  7. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    [L48241,A232573] Pimavanserin was also under review as a potential treatment for dementia-related psychosis; however, as of April 2021, FDA approval has not been granted for this indication despite previous

  8. Drug

    ZEN-012

    go.drugbank.com/drugs/DB06042
    Experimental

    ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties. It is developed for the treatment of solid tumors.

  9. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    As of August 2007 elacridar was not listed on GSK's product pipeline. Development is assumed to have been discontinued.

  10. Drug

    Lunacalcipol

    go.drugbank.com/drugs/DB05024
    Investigational

    Cytochroma anticipates that CTA018 will be more potent than currently marketed vitamin D analogues such as calcitriol and calcipotriol and it is expected to have a greater safety index. … Preclinical studies have shown that CTA018 inhibits the proliferation of rapidly dividing cells such as human epidermal keratinocytes (skin cells) and is also effective in inhibiting pro-inflammatory cytokine